Postprandial hemorrheology and apolipoprotein B metabolism in patients with familial hypertriglyceridemia.
Impaired postprandial lipoprotein metabolism has been found to be related to the extent of coronary artery disease. Moreover, since dyslipoproteinemias are associated with impaired hemorrheology, we investigated the effect of postprandial hypertriglyceridemia on hemorrheological parameters before and after triglyceride-lowering therapy. Triglyceride-rich lipoproteins (TRLs) separated by ultracentrifugation (d < 1.006 g/dL) and chylomicrons and chylomicron remnants (quantified by apolipoprotein [apo] B-48 determination) were determined after a fat load in 10 patients with familial hypertriglyceridemia before and after therapy with gemfibrozil (900 mg daily). Lipid and hemorrheological parameters (plasma and whole-blood viscosity [PV and BV], red cell aggregation [RCA], hematocrit, and fibrinogen) were determined at baseline and every hour up to 6 hours postprandially. Fasting total triglycerides and TRL triglycerides significantly decreased with gemfibrozil therapy (P < .01). Total triglycerides postprandially increased from 9.53 +/- 1.72 to 14.47 +/- 2.07 mmol/L (TRL triglycerides by 61%) before therapy (P < .05) and from 4.61 +/- 1.28 to 7.17 +/- 0.99 mmol/L (TRL triglycerides by 57%) after therapy (P < .05). The postprandial TRL apo B increase was reduced with gemfibrozil (from 11.6 +/- 2.8 to 20.7 +/- 5.0 mg/dL with therapy v 19.0 +/- 7.6 to 33.0 +/- 12.5 mg/dL before therapy, P < .05, respectively) with a proportionally greater increase in apo B-48 (119% and 169%, respectively) compared with apo B-100 (64% and 64%, respectively). Fasting RCA was improved with lipid-lowering therapy (P < .05), but PV, BV, RCA, and fibrinogen did not show any statistically significant postprandial changes either before or after lipid-lowering therapy. In summary, we did not find any statistically significant changes in hemorrheological parameters, despite a strong postprandial increase of triglycerides. In particular, these findings were independent of fasting triglyceride levels. We conclude that triglyceride-lowering therapy by gemfibrozil had no substantial beneficial effects with respect to hemorrheology in patients with familial hypertriglyceridemia.
Otto
C
C
Department of Medicine II, Klinikum Grosshadern, University of Munich, Germany.
Pschierer
V
V
Soennichsen
A C
AC
Schwandt
P
P
Richter
W O
WO
D000328:Adult; D001055:Apolipoproteins B / Q000097:blood* / Q000145:classification / Q000187:drug effects / Q000378:metabolism; D005215:Fasting / Q000097:blood; D005260:Female; D015248:Gemfibrozil / Q000008:administration & dosage; D006400:Hematocrit; D006801:Humans; D006953:Hyperlipoproteinemia Type IV / Q000097:blood* / Q000188:drug therapy / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000008:administration & dosage; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood*; D008297:Male; D019518:Postprandial Period; D012212:Rheology; D013997:Time Factors; D014280:Triglycerides / Q000097:blood* / Q000378:metabolism
D001055:Apolipoproteins B; D000960:Hypolipidemic Agents; D008055:Lipids; D014280:Triglycerides; D015248:Gemfibrozil